IDH1 and acute myeloid leukemia: Discovery of these mutations allowed for pharmacological advancement in small molecular inhibitors such as those targeting mutated isocitrate dehydrogenase 1/2 (IDH1/2) and changed the treatment landscape of relapsed/refractory AML outcomes.